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Abstract
CCR2 is considered a proinflammatory mediator in many inflammatory diseases such as rheumatoid arthritis. However, mice
lacking CCR2 develop exacerbated collagen-induced arthritis. To explore the underlying mechanism, we investigated
whether autoimmune-associated Th17 cells were involved in the pathogenesis of the severe phenotype of autoimmune
arthritis. We found that Th17 cells were expanded approximately 3-fold in the draining lymph nodes of immunized CCR2
2/2
mice compared to WT controls (p=0.017), whereas the number of Th1 cells and regulatory T cells are similar between these
two groups of mice. Consistently, levels of the Th17 cell cytokine IL-17A and Th17 cell-associated cytokines, IL-6 and IL-1b
were approximately 2–6-fold elevated in the serum and 22–28-fold increased in the arthritic joints in CCR2
2/2 mice
compared to WT mice (p=0.04, 0.0004, and 0.01 for IL-17, IL-6, and IL-1b, respectively, in the serum and p=0.009, 0.02, and
0.02 in the joints). Furthermore, type II collagen-specific antibodies were significantly increased, which was accompanied by
B cell and neutrophil expansion in CCR2
2/2 mice. Finally, treatment with an anti-IL-17A antibody modestly reduced the
disease severity in CCR2
2/2 mice. Therefore, we conclude that while we detect markedly enhanced Th17-cell responses in
collagen-induced arthritis in CCR2-deficient mice and IL-17A blockade does have an ameliorating effect, factors additional to
Th17 cells and IL-17A also contribute to the severe autoimmune arthritis seen in CCR2 deficiency. CCR2 may have a
protective role in the pathogenesis of autoimmune arthritis. Our data that monocytes were missing from the spleen while
remained abundant in the bone marrow and joints of immunized CCR2
2/2 mice suggest that there is a potential link
between CCR2-expressing monocytes and Th17 cells during autoimmunity.
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Introduction
Th17 cells are IL-17-producing T helper effector cells that are
distinct from Th1 and Th2 cells, and from regulatory T (Treg)
cells. Th17 cells have been suggested to mediate inflammation and
play a key role in the pathogenesis of tissue-specific autoimmune
diseases including experimental autoimmune encephalomyelitis
(EAE), collagen-induced arthritis (CIA), and psoriasis [1,2].
Specifically, studies found that mice lacking a Th17 cell-promoting
cytokine IL-23 were resistant to EAE or CIA [3], whereas mice
deficient for the classic Th1 cell cytokine IL-12 or IFN-cwere
more susceptible to these diseases [4,5]. Adoptive transfer of Th17
cells was shown to be required for EAE [6]. Furthermore, gene
targeted deletion of IL-17 or treatment with a neutralizing anti-IL-
17 antibody results in CIA resistance [7,8]. These results suggest
that Th17 cells are potent inducers of autoimmune disorders.
Since the IL-17 receptor is expressed on epithelial and
parenchymal cells, Th17 cells are thought to promote tissue
inflammation by producing IL-17 to stimulate the production of
IL-6, IL-1, tumor necrosis factor (TNF), and other proinflamma-
tory factors [9]. In humans, anti-IL-17A antibodies have shown
positive clinical responses and good safety in patients with active
rheumatoid arthritis (RA) in randomized, double-blinded proof-of-
concept trials [10,11], suggesting that targeting of IL-17A is a
promising therapeutic approach against human autoimmune
disease, such as RA.
CCR2 is a chemokine receptor for monocyte chemoattractant
protein-1 (MCP-1 or CCL2) and important for monocyte
trafficking toward sites of inflammation, a process that is critical
for autoimmune diseases like rheumatoid arthritis (RA) and CIA
[12]. Since CCR2 is highly expressed on joint infiltrated
monocytes/macrophages in RA patients and CIA animals [13],
targeted inhibition of CCR2 was initially thought to be a
promising therapeutic strategy for the treatment of RA. However,
clinical trials using CCR2 or CCL2 neutralizing antibodies did not
show efficacy [14,15]. Application of anti-CCR2 during disease
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2/2) unexpectedly
induce exacerbated CIA in mice [13,16]. Although our previous
study and others show that inhibiting CCR2 is beneficial to other
inflammatory diseases, such as vascular inflammations [17,18], the
mechanism underlying the CCR2 paradox in autoimmune
inflammation is not completely understood.
Autoimmune inflammation uniquely involves antigen-specific
activation of T cells that leads to subsequent B cell activation and
autoantibody formation. Given the specific proinflammatory role
of Th17 cells in autoimmune diseases, we hypothesized that
skewing of Th17 cells and Th17-cell responses may account for the
exacerbated arthritis in CCR2
2/2 mice. To test this hypothesis,
we examined Th17 cells, Th1 cells, Treg cells, and Th17 cell-
associated events, such as cytokine profile, autoantibody produc-
tion, and neutrophil activities, in CCR2
2/2 mice induced with
collagen-induced arthritis. We also treated these animals with an
IL-17A neutralizing antibody. Our results demonstrate that both
Th17 cells and Th17-cell associated responses are markedly
enhanced in immunized CCR2
2/2 mice and neutralizing IL-17A
has an ameliorating effect on the severe autoimmune arthritis seen
in CCR2 deficiency. Our data that monocytes decrease in the
spleen, but not in the bone marrow and arthritic joints in CCR2
2/
2 mice suggest a potential biological link between CCR2-
expressing monocytes and Th17 cells.
Methods
CIA induction and evaluations
CCR2
2/2 mice on DBA/1J background were generated by
backcrossing CCR2
2/2 C57BL/6J mice with wildtype DBA/1J
mice (Jackson Laboratory, Bar Harbor, Maine) for 12 generations.
8–10 week-old male CCR2
2/2 DBA/1J mice (CCR2
2/2 mice)
were used in the experiments and the age- and gender-matched
littermates of CCR2
+/+ DBA/1J mice (WT mice) were used as
controls. All mice were bred and maintained in a barrier facility
and fed with Prolab RMH-3000 (PMI Nutrition International,
Richmond, IN), a normal rodent chow diet. All experimental
protocols were in compliance with IACUC (Institutional Animal
Care and Use Committee) guidelines and were approved by the
IACUC at the University of North Carolina at Chapel Hill (ID:
09-344).
CIA is typically performed with either one or two injections of
heterologous type II collagen on a susceptible congenic mouse
strain. The main purpose of a second booster is to increase the
overall disease severity so that the difference between control mice
and gene-deficient or treatment animals that have less disease can
be apparent. In our case, CCR2-deficient mice have exacerbated
disease that starts from day 14 after one injection, which was prior
to the second booster at day 21. Therefore, we chose to utilize
single injection to examine effect of CCR2 deficiency on the
pathogenesis of CIA. In this study, CIA was induced by
immunization with type II bovine collagen (CII, Chondrex,
Redmond, WA) emulsified with complete Freund’s adjuvant
(CFA, Sigma). The immunization and disease evaluation methods
were performed according to protocols validated by our group and
others with minor revisions [19,20]. Briefly, CII was dissolved
overnight in 0.1 M acetic acid and emulsified in an equal volume
of CFA. Mice were immunized with a subcutaneous injection of
100 ml of emulsion containing 100 mg of CII at approximately
1 cm from the base of the tail at day 0. The clinical disease of
arthritis was evaluated as follows: 0=normal; 1=swelling in 1
joint; 2=swelling in .1 joint; 3=swelling of the entire paw. Paw
swelling was measured in mm range with a Dial Thickness gauge
(Geneva Gage, Albany, OR). Both arthritis scoring and measure-
ment were performed in a blinded manner.
Flow cytometry
Single cell suspension of the spleen or draining lymph nodes was
prepared using a manual tissue homogenizer. Red blood cells
(RBC) were lysed with a lysis buffer (0.14 M NH4CI, 0.017 M
Tris-HCl adjust to pH 7.2). Cells were washed with RPMI
containing 2 mM Hepes and 1% bovine serum albumin and
passed through a 70 mm nylon cell strainer. Isolation of synovial
cells was performed as described previously [21] with minor
modifications. Briefly, the hind paws were dissected out and
incubated with Collagenase D (Sigma) at 2 mg/ml in PBS at 37uC
for 30 minutes. The digestion was stopped by adding 10 mM
EDTA and incubated for an additional 5 minutes. Synovial cells
were isolated and passed through a 70 mm cell strainer. A CyAn
flow cytometer and Summit software (CyAn, Dako) were used to
analyze cell surface markers that were stained with fluorophore-
conjugated primary and isotype control antibodies (eBioscience
and Biolegend). Antibodies used in the experiments included anti-
CD3, CD4, CD8, CD45R/B220, CD11b, CD11c, F4/80, Ly6C,
Ly6G and their isotype controls that were conjugated with FITC,
PE, PerCP, Pacific Blue, Pacific Orange, allophycocyanin (APC),
and Alexa Fluor-APC. For intracellular cytokine staining, single
cell suspension of draining lymph nodes were cultured in petri
dishes pre-coated with anti-CD3 in the presence of anti-CD28 for
6 hours, and Golgi Stop (BD Bioscience) was added for the last
two hours. Cells then were harvested and stained with anti-CD4
on the surface, fixed and permeabilized with BD Cytofix/
Cytoperm (BD Bioscience), and stained with anti-IL-17A and
anti-IFN-cintracellularly. For staining of Treg cells, anti-CD4/
CD25 surface stained cells were fixed and permeabilized overnight
at 4uC. The following day the cells were blocked for 15 minutes
with anti-CD16/CD32, and then stained with anti-FoxP3-PE
(eBioscience, San Diego, CA) at 4uC for 30 minutes.
Analysis of systemic cytokine profile
Systemic cytokine profiles of IL-1b, IL-6, IL-17A, and IFN-c
were determined by Luminex using blood sera collected through
submandibular bleeding of CCR2
2/2 and WT mice with CIA.
Sera cytokine levels were measured with a Premixed Beadlyte Kit
(Millipore, Billerica, MA) by the Luminex 100 dual laser system
and XY Platform (Luminex Corp., Austin, TX), which was
controlled by the MasterPlex CT 1.2 software (MiraiBio,
Alameda, CA). MasterPlex QT 4.0 system (MiraiBio, Alameda,
CA) was used for data analysis and the five-parameter regression
formula was used to calculate cytokine concentrations from the
standard curves. All luminex assays were performed by the UNC
Clinical Proteomics Laboratory. BAFF was detected using a
Quantikine Mouse BAFF ELISA Kit from R&D System
(Minneapolis, MN) according to manufacture instruction.
Production of antigen-specific antibodies
The production of antigen-specific antibodies was measured by
ELISA using the Mouse Anti-Bovine Type II Collagen IgG Assay
Kit (Chondrex, Redmond, WA). Briefly, collagen pre-coated wells
were washed and blocked with the blocking buffer and incubated
with mouse sera samples with a 1:10,000 dilution, incubated with
an HRP-labeled polyclonal secondary antibody, and developed
with the OPD solution. OD values were read at 490 nm on an
Emax Precision Microplate Reader and analyzed with SOFTmax
PRO, 3.0 (Molecular Devices).
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The expression of IL-17A in the joint tissues was measured by
quantitative real-time PCR. Briefly, total RNA was isolated from
CIA mouse paws by Trizol followed by a RNA cleaning step using
the Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA), and cDNA
was generated using the First-Strand cDNA Synthesis Superscript
II RT (Invitrogen, Carlsbad, CA). Primers used for the
amplification of murine IL-17A, IFN-c, IL-6, IL-1b, CXCL1,
CXCL2, RANKL and 18s rRNA were as follows: IL-17A, 59-
TCTCTGATGCTGTTGCTGCT-39(forward) and 59-CTCCA-
GAAGGCCCTCAGACTAC-39(reverse); IFN-c,5 9-ACTGG-
CAAAAGGATGGTGAC-39 (forward) and 59-ACCTGTGGG-
TTGTTGACCTC-39 (reverse); IL-6, 59-TTCCATCCAGTT-
GCCTTCTT-39 (forward) and 59-CAGAATTGCCATTGCAC-
AAC-39 (reverse); IL-1b,5 9-GGTCAAAGGTTTGGAAGCAG-
39 (forward) and 59-TGTGAAATGCCACCTTTTGA-39 (re-
verse); CXCL1, 59-CAATGAGCT GCGCTGTCAGTG-39 (for-
ward) and 59-CTTGGGGAC ACCTTT TAGCAT C-39 (re-
verse); CXCL2, 59-CCAAGGGTTGACTTCAAGAAC-39
(forward) and 59-AGCGAGGCACATCAGGTACG-39 (reverse);
RANKL, 59-TGTACTTTCGAGCGCAGATG-39 (forward) and
59-AGGCTTGTTTCATCCTCCTG-39 (reverse) and 18s rRNA,
59-GACCATAAACGATGCCGACT-39 (forward) and 59-
GTGAGGTTTCCCGTGTTGAG-39 (reverse). Quantitative re-
al-time PCR was performed in a SYBR Green Master Mix with
primers listed above in an iCycler instrument (BioRad Laborato-
ries Hercules, CA). The 2
2DDCt method [22] was used for data
analysis.
Anti-IL-17A antibody treatment
CCR2
2/2 mice were immunized for CIA and divided into two
groups of treatment. At day 14 post-immunization, each mouse
was given 200 mg of either a murine anti-IL-17A antibody
(Novartis, Basel, Switzerland) or an isotype control IgG1
(Biolegend, San Diego, CA) through intraperitoneal (i.p.) injection.
Then additional injections were given twice a week for two weeks.
Statistical analysis
Numerical data presented in the text and figures were expressed
as mean 6 SEM. Student’s unpaired two-tail t test was utilized to
compare average numbers of cells or percentages between
experimental groups. For clinical disease assessment and antibody
treatment experiments, arthritis severities were analyzed using a
Mixed Effect Model to determine significances over time in
arthritis scores and paw swelling. The overall group effect was
assessed using a likelihood ratio test (LRT). Analysis was
conducted using SAS, v. 9.2 statistical software package (Cary,
NC). In all cases, p,0.05 was considered significant.
Results
Th17 cells are expanded in the draining lymph nodes and
joints of collagen immunized CCR2
2/2 mice
Both CCR2 and its ligand CCL2 are up-regulated in the
synovium of patients with RA, and thus are considered to be
proinflammatory in autoimmune inflammation [12]. However,
more severe arthritis was developed in CCR2
2/2 mice that were
induced by collagen immunization [13]. Indeed, significant
differences were identified over time for CCR2
2/2 mice in both
the clinical arthritis scores (LRT=26.4, df=4, p,0.0001) and the
paw swelling (LRT-37.5, df=4, p,0.0001) compared to WT
controls (Figure 1A). Disease in CCR2
2/2 mice occurred 14 days
earlier than that in WT controls after one immunization. Between
days 42 and 49 after immunization, 100% of CCR2
2/2 mice and
approximately 40% of WT mice received maximal disease, which
proceeded to the recovery and resolution phase after this period of
time. The severity of arthritis was approximately three times worse
during the follow-up time period in CCR2
2/2 mice with
deteriorated histological changes of leukocyte infiltration, bone
erosion, and joint destruction (Figure 1 B). These results confirm
the previous finding that the absence of CCR2 does not ameliorate
but rather aggravates autoimmune arthritis.
Given that autoimmune arthritis is a T cell-mediated disease;
and Th17 cells are potent inducers of tissue inflammation in this
disease [23], we hypothesized that CCR2 deficiency promotes
autoimmune arthritis by facilitating Th17 cell activities. To test
this hypothesis we examined Th17 cells in immunized CCR2
2/2
and wild type mice. We also tested the abundance of Th1 cells and
Treg cells. Our data showed that the number of Th17 cells was
increased approximately 3-fold in the draining lymph nodes of
CCR2
2/2 mice prior to disease onset (p=0.017), whereas Th1
cells remained similar between CCR2
2/2 and WT mice
(Figure 1C and D). There was no significant difference of Treg
cells in peripheral lymphoid tissues between immunized CCR2
2/2
and wild type mice (Figure 1E).
Consistently, levels of IL-17A, but not IFN-c in the serum of
CCR2
2/2 mice were significantly increased (Figure 2A) in the
early phase of arthritis. In the meantime, serum IL-6 and IL-1b,
which are closely related to Th17 cell differentiation and
downstream Th17 cell-mediated proinflammatory responses, were
also increased in CCR2
2/2 mice (Figure 2A). However, such
significant elevation of sera cytokines in CCR2
2/2 mice became
less obvious when robust joint disease developed (Figure 2B). Then
we went on to test these cytokines in the arthritic joints and found
that the expression levels of IL-17A, IL-6, and IL-1b were up-
regulated in CCR2
2/2 mice compared to WT mice (Figure 2C
and D). These results suggest that CCR2 deficiency induces
increased Th17 cell activities in the generation and development
of autoimmune arthritis.
Increased autoantibody production in CCR2
2/2 mice
IL-17 has been shown to act in synergy with B cell-activating
factor (BAFF) to influence B cell biology in systemic lupus
erythematosus [24]. Therefore we analyzed B cell abundance and
their ability to produce type II collagen (CII)-specific antibodies in
immunized CCR2
2/2 mice. We found that CCR2
2/2 mice have
approximately 26% more B lymphocytes in the draining lymph
nodes than that in WT mice (Figure 3A). In agreement with this
result, significantly higherlevelsof anti-CIIIgG weredetected inthe
serum of these mice (Figure 3B). However, such increased B cell
activities were BAFF-independent as we did not find significant
BAFF elevation in CCR2
2/2 mice (Figure 3C). Thus, the
expansion of Th17 cells in CCR2
2/2 mice appears to be associated
with enhanced humoral immune responsiveness to type II collagen.
Upregulated neutrophils in CCR2
2/2 mice
IL-17 promotes inflammation through stimulation of granulopoi-
esis in vivo [25]. To examine activities of neutrophils in immunized
CCR2
2/2 mice, we investigated the abundance of Ly6-
G
+Ly6C
+CD11b
+ neutrophils in the spleen and the joints. In the
spleen, we found substantially more neutrophils in CCR2
2/2 mice
than in WT mice (Figure 4A and B). Correspondingly, enhanced
neutrophil infiltration into the joints was detected in these mice
(Figure 4A and B). The expansion of neutrophils in CCR2
2/2 mice
was also observed inthe histological joint sections with the H&E stain
(Figure 1B). As neutrophil recruitment is driven by neutrophil-tropic
chemokines, CXCL1 and CXCL2, we examined joint expressions of
these cytokines. Indeed, these cytokines increased substantially in the
Th17 Cells in CCR2-Deficient Autoimmune Arthritis
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25833Figure 1. Th17 cells expand in the draining lymph nodes of immunized CCR2
2/2 mice. A. CCR2
2/2 and WT mice were immunized with
bovine type II collagen in CFA at day 0. Arthritis was measured and recorded in arthritis scores and paw swelling over time. These results are
representative of one of three experiments with a total of 25 mice. B. Representative photos of hind paws (day 26) and their histological sections with
the H&E stain (day 48) from WT and CCR2
2/2 mice are shown. Arrows indicate the extensive inflammation and bone erosion in the joint section of
CCR2
2/2 mice with CIA. C–D. Single cell suspension of the draining lymph nodes of immunized mouse was cultured in medium with or without anti-
CD3 and anti-CD28 antibody stimulation for 6 hours. They were then harvested and stained with anti-CD4 antibody on the surface and anti-IL-17A
and anti-IFN-cantibodies intracellularly. C shows the dot plots of cells gated on CD4
+ cells in flow cytometry, and D demonstrates the average
numbers of Th17 cells versus Th1 cells in the draining lymph nodes of CCR2
2/2 and WT mice 14 days after immunization, each group contains 5
animals, **p=0.017. E. Treg cells were identified from the spleen and lymph nodes of immunized mice as CD4
+CD25
+FoxP3
+ cells. These data are
results of at least three separate experiments.
doi:10.1371/journal.pone.0025833.g001
Figure 2. Serum and joint cytokine profiles favor Th17 cell expansion in CCR2
2/2 mice. A. Blood sera were collected at day 26 after
immunization from WT and CCR2
2/2 mice. Levels of cytokines were measured by Luminex assays. Significant differences indicated as asterisks (**)
were found in IL-1b (p=0.01), IL-6 (p=0.0004), and IL-17 (p=0.04). Eight animals in each group were used. B. Sera levels of cytokines were measured
at day 48 after immunization by Luminex. Four animals in each group were used. C. Joint tissues were isolated from the hind paws of mice at day 48
after immunization. The expression of IL-17 and IFN-c mRNA was measured by quantitative real time PCR in WT (n=5) versus CCR2
2/2 (n=4) mice,
**p=0.009. D. Joint tissues were isolated from the hind paws of mice at day 48 after immunization. The expression of IL-1b and IL-6 mRNA was
measured by real time PCR in WT (n=5) versus CCR2
2/2 (n=4) mice, **p#0.02.
doi:10.1371/journal.pone.0025833.g002
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2/2 mice (Figure 4C). In addition,
increased expression of receptor activator of nuclear factor kappa-B
ligand (RANKL) was also observed in the joint of CCR2
2/2 mice
(Figure 4C). These results indicate that Th17 cell expansion induced
by CCR2 deficiency is associated with cellular responses in collagen-
induced arthritis.
Anti-IL-17A antibody treatment ameliorates CIA in
CCR2
2/2 mice
To confirm a role of IL-17 in the pathogenesis of CCR2-
mediated exacerbation of arthritis, we examined the effect of a
murine anti-IL-17A antibody on the development of CIA in
CCR2
2/2 mice. As shown in Figure 5, CCR2
2/2 mice that were
treated with the anti-IL-17A antibody developed milder disease
than CCR2
2/2 mice that were treated with an isotype control
antibody. In addition, the onset of CIA in the anti-IL-17A treated
group was also delayed. These results indicate that IL-17A
contributes, at least in part, to the exacerbation of collagen-
induced arthritis in CCR2
2/2 mice.
Monocytes decrease in the spleen, but are abundant in
the bone marrow and arthritic joints in immunized
CCR2
2/2 mice
Given that CCR2 is highly expressed on monocytes [26] that
have been recently identified as T cell suppressors under
autoimmune conditions [27], we examined monocytes in immu-
nized CCR2
2/2 mice. We found that Ly6C
highCD11b
+ CCR2-
expressing monocytes were almost absent from the spleen. In
contrast, these monocytes were more abundant in the bone
marrow and the inflamed joints in CCR2
2/2 mice compared to
WT mice. Together, these results indicate that CCR2 mediates
monocyte immigration from the bone marrow while serving no
role in monocyte recruitment to the arthritic joints (Figures 6A–C).
These data also suggest that the lack of CCR2-expressing
monocytes in CCR2
2/2 mice in the spleen after immunization
may promote Th17 cell polarization and proliferation in the
priming phase of collagen induced arthritis.
Discussion
CCR2 is a chemokine receptor predominantly expressed on
monocytes and is considered proinflammatory in response to
inflammation. However, CCR2 deficiency unexpectedly induces
severe autoimmune arthritis with accelerated disease onset; and
the underlying mechanism is not completely understood. In this
study, we show that Th17 cells are selectively expanded prior to
disease onset in the draining lymph nodes in collagen-immunized
CCR2
2/2 mice compared to WT controls. Consistently, aug-
mented IL-17A, IL-6, and IL-1b levels are observed in the blood
and in the inflamed joints of CCR2
2/2 mice, which are
Figure 3. Antigen-specific antibodies increase with B cell expansion in CCR2
2/2 mice. A. Single cell suspensions were isolated from the
draining lymph nodes of mice at day 14 after immunization. B cells were identified as CD45R/B220
+ cells by flow cytometry. Data shown are average
numbers of B cells from WT (n=6) and CCR2
2/2 mice (n=4), **p=0.0004. B. Blood sera were collected from WT (n=7) and CCR2
2/2 mice (n=8) at
day 26 after immunization, and levels of anti-type II collagen antibodies (anti-CII) were determined by ELISA, **p=0.005. C. ELISA results of serum
levels of BAFF of WT and CCR2
2/2 mice at day 14 (n=4 vs. 5), day 21 (n=7 vs. 8), and day 26 (n=7 vs. n=5) after immunization are shown.
doi:10.1371/journal.pone.0025833.g003
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phil infiltration. Neutralizing IL-17A has an ameliorating effect on
the severe arthritis observed in CCR2
2/2 mice. Our results
suggest a previously unrecognized mechanism that CCR2 may be
important in maintaining immunological homeostasis and pro-
tecting against collagen-induced arthritis via regulation of Th17
cell responses. Given that monocytes suppress T cell function
during autoimmunity, our finding that monocytes are substantially
decreased in the spleen but not in the bone marrow and the
arthritic joints in CCR2
2/2 mice may provide a biological link
between CCR2 and Th17 cells during the pathogenesis of
collagen-induced arthritis.
Accumulated evidence has implicated an important role for
Th17 cells in autoimmune disease such as RA [28,29,30]. Th17
cell differentiation from naı ¨ve CD4+ T cells depends on IL-6 and
TGF-b production. Given that TGF-b is also required for Treg
cell generation and IL-6 can reverse Treg cell-mediated
suppression of autoreactive T cells [31], IL-6 is an essential
differentiation factor for Th17 polarization. On the other hand,
IL-17 activates cells in synovium, such as synovial fibroblasts and
monocytes/macrophages, to produce IL-6, IL-1 and TNF-a and
thus sustain joint inflammation [32,33,34]. Consistent with these
findings, ourdatashow that earlyTh17 cell expansion inCCR2
2/2
mice is accompanied by elevated IL-6 levels in the blood. Increased
levels of IL-17A expression are also observed together with
augmented IL-6 and IL-1b abundance in the arthritic joints of
CCR2
2/2 mice. Additionally, RANKL expression is significantly
up-regulated in CCR2-deficient joints, which is consistent with
findings that joint IL-17A stimulates osteoclasts to express RANKL
that promotes bone erosion [35,36]. Together, our results support
the hypothesis that a positive feedback loop between Th17 cells and
IL-6 is a key factor involved in tolerance breakdown and tissue
injury in autoimmune arthritis. Our data further suggest a potential
beneficial role of CCR2 in this process.
Th17 cells promote autoimmune pathology through effects on
cellular and humoral immune responses. Indeed, increased Th17
cells are not only accompanied by a substantial expansion of
neutrophils in both the spleen and joints but also B cell up-
regulation with a consequent elevation of type II collagen-specific
antibodies in immunized CCR2
2/2 mice. IL-17A is known to
stimulate granulopoiesis in vivo [25] and stimulates neutrophil-
specific chemokines such as MIP-2 and IL-8 [37]. Blockade of IL-
17A in IFN-c receptor knockout mice with CIA ameliorates joint
inflammation and bone erosion by significant reductions of the
splenic expansion and joint influx of neutrophils [38], suggesting a
critical role of IL-17-stimulated neutrophils in autoimmune
pathology. IL-17 receptor is expressed on B cells, and IL-17 has
been shown to work together with B cell-activating factor to
control the survival and differentiation of B cells into antibody
producing cells in autoimmunity [24,39]. In addition, IL-17 is
found to drive autoimmune responses by promoting the formation
of spontaneous germinal centers [40], and IL-17A-deficient mice
have decreased autoantibodies in CIA and EAE [7,41]. These
results provide rationales for our data that increased Th17-cell
responses contribute to the exacerbated arthritis in CCR2
2/2
mice.
Recently, Fuji et al. have published a well-designed study
showing that ablation of the Ccr2 gene exacerbated polyarthritis in
IL-1 receptor antagonist-deficient (Il1rn
2/2) mice [42]. Increased
neutrophil accumulation and IL-I7 production were observed in
the inflamed joints of those double knockout mice. Neutralizing
CXCR2, a neutrophil chemokine receptor, reduced arthritis
severity in Il1rn
2/2Ccr2
2/2 mice. Since our collagen-induced
arthritis model is different from the Il1rn-dependent model in
which polyarthritis develops spontaneously [43], it is difficult to
compare directly which therapeutic method, anti-IL-17A or anti-
CXCR2 is more effective. It is possible that the augmented
neutrophil infiltration into the joints in CCR2
2/2 mice contribute
to the aggravated disease process through an additional Th17-
independent mechanism. However, since neutrophils are key
innate cells against infection, targeting such cells for the treatment
of chronic disease like RA needs to be done cautiously.
Monocytes traffic to tissues and differentiate into macrophages
or dendritic cells in response to inflammation [44,45]. Recent
evidence shows that CCR2 does not mediate monocyte trafficking
into the inflamed tissues [46,47], but is rather involved in the
Figure 5. Treatment with anti-IL-17A antibodies reduces CIA in
CCR2
2/2 mice. CCR2
2/2 mice were immunized with bovine type II
collagen at day 0 and were treated 5 times in 2.5 weeks with either an
anti-IL-17A antibody (Treated, n=5) or an isotype control IgG1 (Control,
n=7) starting from day 14 after immunization. Arthritis score (A) and
paw swelling (B) were recorded over time (Days). Data represent one of
the two independent experiments performed. Differences of both
arthritis scores and paw swelling during the course of disease between
treated and control groups are significant (p,0.01).
doi:10.1371/journal.pone.0025833.g005
Figure 4. Neutrophil infiltration increases in the spleen and the joints of CCR2
2/2 mice. Cells were isolated from the spleen and the hind
paws of mice at day 48 after immunization and were stained for flow cytometry analysis. Ly6G
+CD11b
+ (Ly6C
+) cells were gated as neutrophils.
Shown are representative dot plots (A) and quantification of the number of neutrophils (B) of three experiments, **p=0.02 in the spleen and 0.002 in
the joints. C. Joint tissues were isolated from the hind paws of mice at day 48 after immunization. The expression of CXCL1, CXCL2, and RANKL mRNA
was measured by real time PCR in WT (n=5) versus CCR2
2/2 (n=4) mice, p=0.059, 0.016, 0.026, respectively.
doi:10.1371/journal.pone.0025833.g004
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e25833Figure 6. Monocytes decrease in the spleen, but are abundant in the bone marrow and arthritic joints in immunized CCR2
2/2 mice.
Single cell suspensions of the spleen, joints, and bone marrow from collagen-immunized mice were labeled with corresponding antibodies. The
monocyte populations were recognized by flow cytometry as L6C
highCD11b
+Ly6G
2 cells (A). The abundance of monocytes in each compartment was
quantified as percentage (B) and number of monocytes per 10
4 of total gated live cells (C) in immunized CCR2
2/2 and WT mice. These data are results
of at least three separated experiments, **p,0.05.
doi:10.1371/journal.pone.0025833.g006
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monocytes are almost absent from the spleen, but are abundant in
the bone marrow and inflamed joints in immunized CCR2
2/2
mice. Intriguingly, CCR2-expressing monocytes have been
recently shown to have an immune regulatory role via suppression
of T cell activities under tumor and autoimmune conditions
[27,49]. It is conceivable that CCR2 deficiency alters T-cell
suppressive monocytes, which results in Th17 cell expansion.
CCR2 is also expressed on a subset of Treg cells that inhibit T cell
proliferation in vitro [50]. However, we find similar numbers of
Treg cells between immunized CCR2
2/2 and WT mice,
suggesting that upregulated Th17 cells in CCR2
2/2 mice are
Treg-cell-independent. But our data cannot exclude the possibility
that a small subset of Treg cells is affected by CCR2 deficiency.
Although CCR2 is a drug target for the treatment of some
inflammatory conditions, blocking CCR2 or deleting Ccr2 gene
worsens autoimmune arthritis. Our data show that Th17 cell
dysregulation is responsible, at least in part, for the exacerbated
phenotype in CCR2-deficient mice. CCR2 may have a protective
role against autoimmune arthritis. Neutralization of IL-17 is a
promising therapeutic approach against autoimmune arthritis
possibly by inhibiting the excessive joint recruitment of neutrophils
and monocytes as local injection and expression of IL-17 promote
migration of both cell types to the joints [51,52].
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